Highlights
• Neurizon shares gained 4% to AUD 0.078 on 1 April 2026 following a scientific update
• New preclinical data show NUZ-001 activates multiple protein clearance pathways
• Evidence supports improved removal of harmful protein build-up in neurons
• Findings reinforce a differentiated multi-pathway approach for neurodegenerative diseases
• Results add to growing evidence as NUZ-001 advances through clinical evaluation

Neurizon Therapeutics Ltd (ASX:NUZ) shares rose 4% to AUD 0.078 on 1 April 2026 after the company released new preclinical data for its lead drug candidate, NUZ-001. Despite today’s gain, the stock remains down approximately 35% over the past year, with the latest update appearing to support renewed investor interest in the company’s scientific progress.

New Data Highlights Mechanism Behind NUZ-001

Neurizon announced new laboratory findings that provide deeper insight into how NUZ-001 works at a cellular level. The data show that the drug increases the activity of multiple natural processes that help cells clear unwanted or damaged proteins.

This is particularly important in neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), where harmful protein build-up inside nerve cells is a key factor driving disease progression.

By improving how cells manage and remove these proteins, NUZ-001 may help support healthier neuron function.

Simplifying the Science: How NUZ-001 Works

In simple terms, cells have built-in systems that act like “clean-up crews” to remove damaged or excess proteins. In diseases like ALS, these systems can become overwhelmed, leading to a build-up of toxic protein clumps that damage nerve cells.

The new data show that NUZ-001 boosts two of these important clean-up systems:

  • Autophagy, which clears larger or bulk protein build-up
  • Proteasome system, which removes smaller or specific protein fragments

By activating both systems at the same time, NUZ-001 helps improve the overall ability of cells to maintain balance and function properly.

This dual action is important because many treatments focus on only one pathway, whereas NUZ-001 targets multiple processes simultaneously.

Evidence from Preclinical Studies

The findings are based on controlled laboratory studies using human-derived neuronal models designed to replicate real biological conditions.

Researchers observed that treatment with NUZ-001 led to changes in key markers associated with protein clearance. These changes indicate that cells were more effectively processing and removing accumulated proteins.

At the same time, there was a measurable increase in the activity of the proteasome system, providing further evidence that the drug activates more than one pathway involved in maintaining cellular health.

Together, these results demonstrate that NUZ-001 works across multiple biological systems that are essential for managing protein balance in nerve cells.

A Broader Approach to Neurodegenerative Disease

One of the key takeaways from the update is that NUZ-001 represents a broader, multi-pathway approach to treating neurodegenerative diseases.

In conditions like ALS, disruption of protein clearance is widely recognised as a central issue. By targeting multiple mechanisms involved in this process, NUZ-001 may offer a more comprehensive way to address the underlying biology of the disease.

This approach could potentially improve the resilience of neurons by helping them better cope with stress caused by protein accumulation.

Strengthening the Scientific Foundation

The latest findings build on existing research and further define the biological activity of NUZ-001. While the results are preclinical, meaning they are based on laboratory studies rather than human trials, they contribute to a growing body of evidence supporting the drug’s development.

The data also support the ongoing clinical evaluation of NUZ-001, including its participation in broader research programs focused on ALS.

By continuing to generate supporting evidence, Neurizon is working to establish a clearer understanding of how its lead candidate may perform in real-world treatment settings.

Company Overview and Focus

Neurizon Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its primary focus is on ALS, the most common form of motor neurone disease.

The company’s strategy is centred on advancing NUZ-001 through clinical development while also exploring its potential applications in other related neurological conditions.

Through ongoing research and collaboration, Neurizon aims to address unmet medical needs in diseases where treatment options remain limited.

What This Means for Investors?

Today’s share price movement appears to reflect a positive response to the latest scientific update, which provides additional clarity on how NUZ-001 functions at a biological level.

While the company remains in the clinical development stage and the stock has declined over the past year, the new data strengthen the scientific rationale behind its lead drug candidate.

Investors are likely to monitor further clinical progress and upcoming trial developments, as these will be key in determining the future potential of NUZ-001.